INVESTIGADORES
VINDEROLA Celso Gabriel
congresos y reuniones científicas
Título:
The effect of spray-drying on the protective capacity of the breastmilk derived Bifidobacterium animalis subsp. lactis INL1 on acute and chronic colitis in mice
Autor/es:
BURNS P; ALARD, J; HRDY, J.; BOUTILLIER, D; PÁEZ R; REINHEIMER, J.A.; POT, B; C.G. VINDEROLA; GRANGETTE, C.
Reunión:
Simposio; The 26th Annual BioCity Symposium: Microbes R Us, Mauno Conference Center; 2016
Resumen:
Gut microbiota dysbiosis seems to play a central role in the development and perpetuation of chronic inflammation in inflammatory bowel disease (IBD), and as such, it is a key target for probiotic intervention, in a strain-specific manner. Differences in the composition of gut microbiota of people from different geographical regions, and their dietary habits, may offer a possibility for the development of locally sourced microbes with health-promoting effects. It is also important to be able to produce large amounts of probiotic biomass using locally available low-cost technologies, especially in emerging countries. Spray drying is a dehydration technology 70-80% less expensive than freeze-drying; however, successful spray drying of probiotics is strain dependent. In the present study, we compared the anti-inflammatory capacities of Bifidobacterium animalis subsp. lactis (B. lactis) INL1, isolated in Argentina from human breast milk, with those of the commercial strain B. lactis Bb12. The impact of spray-drying on the functionality of both strains of bifidobacteria was also investigated in a TNBS-induced acute and chronic colitis mouse model (Wallace and Ameho score and qRT-PCR quantification of cytokine´s expression in colon samples after bifidobacteria and TNBS administration). We concluded that the drying process did not affect bacterial survival to spray drying and that both strains were able to exhibit protective capacities against acute and chronic colitis in mice that were not affected by the dehydration technology used. This work opens new perspectives for the use of B. lactis INL1 targeting populations with IBD in Argentina.